Biogen Misses EPS, Exceeds Revenue; BG-12 Launch Next
By Jennifer Boggs
Monday, January 28, 2013
Biogen Idec Inc.'s fourth-quarter earnings missed estimates, but Wall Street barely noticed as revenue topped expectations, driven largely by steady growth in multiple sclerosis (MS) drugs Avonex (interferon beta-1a) and Tysabri (natalizumab), with investors already looking ahead to the much-anticipated launch of oral MS drug BG-12.
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.